Tacrolimus news

All news on Tacrolimus (also known as FK506, Prograf, Advagraf, Astagraf XL, and Envarsus XR): plants, production capacities, investments and involved companies.

15 July 2026

Roche: FDA grants Priority Review for Gazyva/Gazyvaro (obinutuzumab) in primary membranous nephropathy

Priority Review follows MAJESTY phase III showing 36.9% complete remission at two years vs 5.7% with tacrolimus; FDA decision expected by Nov 2026.
14 July 2026

Genentech’s Gazyva (obinutuzumab) granted FDA priority review for primary membranous nephropathy

FDA granted priority review for obinutuzumab in pMN after Phase III MAJESTY showed markedly higher complete remission vs tacrolimus; FDA decision expected Nov 2026.
16 February 2026

Roche Reports Positive Phase III Results for Gazyva in Membranous Nephropathy

Phase III study shows Gazyva achieves higher remission rates in membranous nephropathy, with safety consistent and no new signals. Data to be shared with health authorities.
15 February 2026

Genentech's Gazyva Shows Positive Phase III Results in Primary Membranous Nephropathy

Phase III study shows Gazyva achieves significant remission in primary membranous nephropathy, with safety profile consistent and no new signals. Data to be shared with health authorities.

Who will be producing Tacrolimus in the future?

Find out with chemXplore Alpha

Learn more